- Home
- GNK vs GERN Comparison
GNK vs GERN Comparison
Compare GNK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNK | GERN |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 967.7M | 1.1B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNK | GERN |
|---|---|---|
| Price | $24.72 | $1.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $19.00 | $2.17 |
| AVG Volume (30 Days) | 270.0K | ★ 15.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $342,054,000.00 | N/A |
| Revenue This Year | $21.15 | $26.91 |
| Revenue Next Year | $1.41 | $43.75 |
| P/E Ratio | $117.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.66 | $1.04 |
| 52 Week High | $27.25 | $2.01 |
Technical Indicators
Market Signals| Indicator | GNK | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 32.86 |
| Support Level | $22.40 | $1.24 |
| Resistance Level | N/A | $1.49 |
| Average True Range (ATR) | 0.90 | 0.09 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 27.45 | 0.00 |
Price Performance
Historical ComparisonAbout GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.